Profound Medical (PROF) Common Equity (2018 - 2026)

Profound Medical's Common Equity history runs 9 years deep, the most recent figure standing at $59.4 million for Q1 2026.

• On a quarterly basis, Common Equity rose 17.0% year-over-year to $59.4 million in Q1 2026; TTM through Mar 2026 was $59.4 million, a 17.0% increase from a year earlier, with the FY2025 full-year figure at $66.4 million, up 9.95% from the prior year.
• Common Equity eased to $59.4 million in Q1 2026 per PROF's latest filing, from $66.4 million in the prior quarter.
• Across five years, Common Equity topped out at $66.4 million in Q4 2025 and bottomed at $30.7 million in Q3 2024.
• The 5-year median for Common Equity is $45.5 million (2024), against an average of $46.1 million.
• Across the five-year window, Common Equity sank 40.64% in 2023 and surged 93.51% in 2024, its largest moves.
• Year by year, Common Equity stood at $52.6 million in 2022, then sank by 40.64% to $31.2 million in 2023, then jumped by 93.51% to $60.4 million in 2024, then grew by 9.95% to $66.4 million in 2025, then declined by 10.55% to $59.4 million in 2026.
• Per Business Quant, the three latest PROF Common Equity figures stand at $59.4 million (Q1 2026), $66.4 million (Q4 2025), and $32.1 million (Q3 2025).